Mandate

Vinge advises EQT VIII in connection with the acquisition of Recover Nordic

December 10, 2019 M&A

Vinge has advised EQT VIII in connection with the acquisition of Recover Nordic from funds advised by Agilitas Private Equity.

Recover Nordic is a Nordic market leader in property remediation and environmental services, primarily serving insurance companies, municipalities, industrial- and commercial clients. Headquartered in Oslo, Norway and with more than 90 branches across the Nordics, the Company has over 2,100 employees and is expected to generate revenues of NOK 3.0 billion in 2019.

The transaction is expected to close in the first quarter of 2020.

Vinge’s team consisted of Daniel Rosvall, Johanna Wiberg, Christian Brelin and Ellinor Wargenbrant (M&A), Johan Cederblad and Cornelia Medrek (Environment), Josefine Lanker and Axel Jansson (Banking and Financing), Mathilda Persson, Rebecka Maltenius, Martin Boström and Lisa Hörnqvist (Commercial Agreements and IT), Emma Johansson (Competition and Regulatory), Lisa Ullman and Ebba Svenburg (Employment) and Kristoffer Larson (Real Property).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025